About: Vaccination in Multiple Sclerosis: Friend or Foe?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccination in Multiple Sclerosis: Friend or Foe? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccination in Multiple Sclerosis: Friend or Foe?
Creator	Wimmer, Isabella Zettl, Uwe Boxberger, Nina Hochmeister, Sonja Kollaritsch, Herwig Loebermann, Micha Meinl, Edgar Rommer, Paulus Winkelmann, Alexander Zrzavy, Tobias
Source	PMC
abstract	Multiple sclerosis (MS) is a debilitating disease of the central nervous systems (CNS). Disease-modifying treatments (including immunosuppressive treatments) have shown positive effects on the disease course, but are associated with systemic consequences on the immune system and may increase the risk of infections and alter vaccine efficiency. Therefore, vaccination of MS patients is of major interest. Over the last years, vaccine hesitancy has steadily grown especially in Western countries, partly due to fear of sequelae arising from vaccination, especially neurological disorders. The interaction of vaccination and MS has been discussed for decades. In this review, we highlight the immunology of vaccination, provide a review of literature and discuss the clinical consideration of MS, vaccination and immunosuppression. In conclusion, there is consensus that MS cannot be caused by vaccines, neither by inactivated nor by live vaccines. However, particular attention should be paid to two aspects: First, in immunocompromised patients, live vaccines may lead to a stronger immune reaction with signs of the disease against which the patients have been vaccinated, albeit in weakened form. Second, protection provided by vaccination should be controlled in patients who have been vaccinated while receiving immunomodulatory or immunosuppressive treatment. In conclusion, there is evidence that systemic infections can worsen MS, thus vaccination will lower the risk of relapses by reducing the risk of infections. Therefore, vaccination should be in general recommended to MS patients.
has issue date	2019-08-07(xsd:dateTime)
bibo:doi	10.3389/fimmu.2019.01883
bibo:pmid	31440255
has license	cc-by
sha1sum (hex)	ac03f138574464ac7c9bfbeee803ebcf3db5e26c
schema:url	https://doi.org/10.3389/fimmu.2019.01883
resource representing a document's title	Vaccination in Multiple Sclerosis: Friend or Foe?
has PubMed Central identifier	PMC6693409
has PubMed identifier	31440255
schema:publication	Front Immunol
resource representing a document's body	covid:ac03f138574464ac7c9bfbeee803ebcf3db5e26c#body_text
is schema:about of	named entity 'IMMUNOLOGY' named entity 'LIVE VACCINES' named entity 'YEARS' named entity 'CONSEQUENCES' named entity 'RECOMMENDED' named entity 'CLINICAL' covid:arg/ac03f138574464ac7c9bfbeee803ebcf3db5e26c named entity 'vaccination' named entity 'EudraVigilance' named entity 'infection' named entity 'immunology' named entity 'Disease-modifying' named entity 'neurological disorders' named entity 'immunosuppression' named entity 'immunology' named entity 'vaccine' named entity 'immunomodulatory' named entity 'Western' named entity 'Vaccination' named entity 'epitope' named entity 'adjuvants' named entity 'varicella infection' named entity 'immunization' named entity 'vaccination' named entity 'immunosuppressive' named entity 'antigens presented' named entity 'hepatitis' named entity 'TLR agonist' named entity 'FDA' named entity 'influenza vaccine' named entity 'MMR' named entity 'polysaccharides' named entity 'hepatitis' named entity 'vaccination' named entity 'papillomavirus' named entity 'post-market surveillance' named entity 'vaccination' named entity 'class IV' named entity 'salts' named entity 'autoimmune disorders' named entity 'polio' named entity 'diphtheria' named entity 'health systems' named entity 'CD4' named entity 'Freund's adjuvant' named entity 'epitope' named entity 'co-stimulatory signals' named entity 'meningitis' named entity 'influenza vaccination' named entity 'induced immunity' named entity 'ADEM' named entity 'follicular dendritic cells' named entity 'immunological effects' named entity 'vaccine' named entity 'VAERS' named entity 'varicella vaccination' named entity 'subunit vaccine' named entity 'seropositive' named entity 'iatrogenic' named entity 'alemtuzumab' named entity 'cytokines' named entity 'haemophilus influenzae' named entity 'rubella' named entity 'antigen' named entity 'immunization' named entity 'immunization' named entity 'CD8 +' named entity 'immunology' named entity 'H5N1' named entity 'acute infection' named entity 'squalene' named entity 'MS patients'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software